Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 291-303 , June 2009

Atherogenesis and atherothrombosis – focus on diabetes mellitus

  • Bernd Stratmann, PhD, Research Director
    • ,
  • Diethelm Tschoepe, MD (Dr h.c., Medical Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 57 31 97 2292; Fax: +49 57 31 97 2122.

References 

  1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. The Journal of the American Medical Association. 1979;241:2035–2038
  2. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998;21:1138–1145
  3. Badimon L, Badimon JJ, Vilahur G, et al. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiology of Haemostasis and Thrombosis. 2002;32:225–231
  4. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. The Journal of the American Medical Association. 2007;297:1197–1206
  5. Viles-Gonzalez JF, Anand SX, Valdiviezo C, et al. Update in atherothrombotic disease. The Mount Sinai Journal of Medicine, New York. 2004;71:197–208
  6. Stary HC. Composition and classification of human atherosclerotic lesions. Virchows Archiv. A, Pathological Anatomy and Histopathology. 1992;421:277–290
  7. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462–2478
  8. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–1374
  9. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  10. Schwartz SM, deBlois D, O'Brien ER. The intima. Soil for atherosclerosis and restenosis. Circulation Research. 1995;77:445–465
  11. Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes. 1993;42:8–11
  12. U.K. prospective diabetes study 16 . Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective diabetes study group. Diabetes. 1995;44:1249–1258
  13. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146
  14. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the second joint task force of European and other societies on coronary prevention. Blood Press. 1998;7:262–269
  15. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527–3561
  16. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. The American Journal of Cardiology. 2002;90:40L–48L
  17. Weiss N, Keller C, Hoffmann U, et al. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vascular Medicine. 2002;7:227–239
  18. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:2839–2843
  19. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine. 2005;352:1685–1695
  20. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–1115
  21. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation. 2001;104:2498–2502
  22. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001;104:2376–2383
  23. Tall AR, Jiang X, Luo Y, et al. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1185–1188
  24. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circulation Research. 2004;95:764–772
  25. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Medical Weekly. 2002;132:241–252
  26. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes & Metabolism. 2003;29:6S44–6S52
  27. Howard BV, Rodriguez BL, Bennett PH, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation. 2002;105:e132–e137
  28. Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care. 1992;15:1141–1155
  29. Celentano A, Vaccaro O, Tammaro P, et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. The American Journal of Cardiology. 1995;76:1173–1176
  30. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European diabetes epidemiology group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617–621
  31. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. European Journal of Cardiovascular Nursing. 2002;1:273–288
  32. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematology/Oncology Clinics of North America. 1990;4:1–26
  33. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. The New England Journal of Medicine. 1995;332:1553–1559
  34. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension. 1988;12:530–548
  35. Hajek AS, Joist JH, Baker RK, et al. Demonstration and partial characterization of insulin receptors in human platelets. The Journal of Clinical Investigation. 1979;63:1060–1065
  36. Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. Journal of Diabetes and Its Complications. 2002;16:35–40
  37. Anfossi G, Mularoni EM, Burzacca S, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121–126
  38. Betteridge DJ, El Tahir KE, Reckless JP, et al. Platelets from diabetic subjects show diminished sensitivity to prostacyclin. European Journal of Clinical Investigation. 1982;12:395–398
  39. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476–1485
  40. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diabetes & Vascular Disease Research. 2005;2:16–23
  41. Jorgensen L. ADP-induced platelet aggregation in the microcirculation of pig myocardium and rabbit kidneys. Journal of Thrombosis and Haemostasis. 2005;3:1119–1124
  42. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99:4486–4493
  43. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. The Journal of Experimental Medicine. 1998;187:329–339
  44. Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96:1809–1818
  45. Frenette PS, Johnson RC, Hynes RO, et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:7450–7454
  46. Massberg S, Enders G, Leiderer R, et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood. 1998;92:507–515
  47. Frenette PS, Denis CV, Weiss L, et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. The Journal of Experimental Medicine. 2000;191:1413–1422
  48. Frenette PS, Moyna C, Hartwell DW, et al. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998;91:1318–1324
  49. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Medicine. 2003;9:61–67
  50. Gawaz MP, Loftus JC, Bajt ML, et al. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIB-IIIA) dependent homotypic and heterotypic cell-cell interactions. The Journal of Clinical Investigation. 1991;88:1128–1134
  51. Massberg S, Schurzinger K, Lorenz M, et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation. 2005;112:1180–1188
  52. Tschoepe D, Roesen P, Schwippert B, et al. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Seminars in Thrombosis and Hemostasis. 1993;19:122–128
  53. Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Seminars in Hematology. 1986;23:8–26
  54. Yazbek N, Bapat A, Kleiman N. Platelet abnormalities in diabetes mellitus. Coronary Artery Disease. 2003;14:365–371
  55. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). The New England Journal of Medicine. 1992;326:242–250
  56. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Hormone and Metabolic Research. 1997;29:631–635
  57. Rauch U, Ziegler D, Piolot R, et al. Platelet activation in diabetic cardiovascular autonomic neuropathy. Diabetic Medicine. 1999;16:848–852
  58. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovascular Research. 1996;32:743–751
  59. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1177–1178
  60. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. The Journal of the American Medical Association. 2000;283:3223–3229
  61. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. Annals of Internal Medicine. 2001;135:801–811
  62. Pohl T, Seiler C, Billinger M, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. Journal of the American College of Cardiology. 2001;38:1872–1878
  63. Werner GS, Ferrari M, Betge S, et al. Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion. Circulation. 2001;104:2784–2790
  64. Libby P, Ridker PM. Inflammation and atherothrombosis - from population biology and bench research to clinical practise. Journal of the American College of Cardiology. 2006;48:A33–A46
  65. Valgimigli M, Agostoni P, Serruys PW. Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. Journal of Cardiovascular Medicine (Hagerstown, Md.). 2007;8:221–229
  66. Kragel AH, Gertz SD, Roberts WC. Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. Journal of the American College of Cardiology. 1991;18:801–808
  67. Virmani R, Burke AP, Kolodgie FD, et al. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. Journal of Interventional Cardiology. 2003;16:267–272
  68. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. British Heart Journal. 1993;69:377–381
  69. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  70. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1262–1275
  71. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994;90:775–778
  72. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994;90:1669–1678
  73. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565–1569
  74. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation. 2001;104:1878–1880
  75. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. The New England Journal of Medicine. 2003;349:2316–2325
  76. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2054–2061
  77. Cola C, Clementi E, Biondi-Zoccai G, et al. From carotid plaque biology to serologic markers of vulnerability to predict the risk of cerebrovascular events. Acta Chirurgica Belgica. 2007;107:129–142
  78. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354–1363
  79. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93:914–921
  80. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. The Journal of the American Medical Association. 2007;297:499–508
  81. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. The New England Journal of Medicine. 2007;357:1301–1310
  82. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. The Journal of the American Medical Association. 2008;299:1561–1573
  83. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology. 2007;49:1982–1988
  84. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2007;357:2001–2015
  85. Negrean M, Stirban A, Stratmann B, et al. Effects of low- and high-advanced glycation end product meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. The American Journal of Clinical Nutrition. 2007;85:1236–1243
  86. Schaar JA, Muller JE, Falk E, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. European Heart Journal. 2004;25:1077–1082

PII: S1521-690X(08)00173-5

doi: 10.1016/j.beem.2008.12.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 291-303 , June 2009

Article Tools

* Image Usage & Resolution